patent/JP-2003519652-A

Predicate	Object
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
filingDate	2001-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate	2003-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	JP-2003519652-A
titleOfInvention	Treatment of diabetic ulcer
abstract	(57) [Summary]nThe present invention relates to the use of cyclic guanosine 3 ', 5'-monophosphate phosphodiesterase type 5 (cGMP PDE5) inhibitors, particularly comprising the compound sildenafil, for the treatment of diabetic ulcers, especially diabetic leg ulcers.
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008526907-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021506983-A
priorityDate	2000-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398744 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394502

Total number of triples: 19.